Status:
UNKNOWN
Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Meningioma, Malignant
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
This research study is studying a drug as a possible treatment for High Grade Meningioma.
Detailed Description
Meningioma is one of the most common primary intracranial tumors, accounting for 13% to 26% of all intracranial tumors. Although most meningiomas are benign tumors and can be cured by surgical resecti...
Eligibility Criteria
Inclusion
- Pathologically diagnosed as a patient with WHO grade III recurrent meningioma
- Age ≥ 18 years
- Kps≥70
- able to accept second surgery
- ECOG Performance Status \< 2
- Glucocorticoid dosage dexamethasone ≤5mg/ day or equivalent dose
Exclusion
- Participants who have had chemotherapy, targeted small molecule therapy or study therapy within 14 days of protocol treatment, or those who have not recovered (i.e., ≤ Grade 1 or at baseline) from adverse events due to agents administered more than 2 weeks earlier.
- Participants who are receiving any other investigational agents.
- Participants who have a diagnosis of an immunodeficiency.
- Requires treatment with high dose systemic corticosteroids defined as dexamethasone \>2mg/day or bioequivalent within 7 days of initiating therapy.
- Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent. Unable to undergo brain MRI.
Key Trial Info
Start Date :
June 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 1 2025
Estimated Enrollment :
15 Patients enrolled
Trial Details
Trial ID
NCT04728568
Start Date
June 1 2020
End Date
June 1 2025
Last Update
August 10 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing TianTan Hospital
Beijing, Beijing Municipality, China, 100071